Joi+Blokes Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A medication name is not the same thing as evidence for an entire care program. That distinction matters at Joi+Blokes, where compounded semaglutide and tirzepatide appear alongside compounded liraglutide, branded Zepbound, coaching and laboratory services. The public documentation gives prospective patients meaningful information about products, prices and responsibilities. It does not establish that the platform’s particular formulations or service model produce the outcomes reported in major drug trials.

This review examines the pages consulted October 19, 2026, separating documented commercial offerings from clinical evidence and unresolved operational questions. Joi+Blokes describes itself in its terms as a platform connecting patients with independent medical providers rather than directly practicing medicine. Its strongest disclosures concern advertised program components and the separate Zepbound purchasing channel. Its weakest points are the relationship between promotional promises and contractual rules, and the limited detail about formulation-specific evidence, follow-up schedules and delivery safeguards.

At a glance

Platform role: The terms say Joi+Blokes does not practice medicine or provide healthcare directly; it connects users with third-party medical providers.
Sources: [8]
Compounded injection pricing: Compounded subcutaneous semaglutide is advertised at $179/month, with the first month $99; compounded subcutaneous tirzepatide is $249/month, with the first month $149. Both are billed quarterly and include medication, dosing support, clinician consultations and coaching.
Sources: [7]
Separate Zepbound charges: The Zepbound service costs $99/month, charged as $297 for three months, excluding medication. Listed Lilly Direct vial purchases are cash-only and not eligible for insurance coverage.
Sources: [5]
Evidence boundary: The provider acknowledges that compounded GLP-1 preparations are not FDA approved. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug.
Sources: [7] [1]
Unresolved subscription terms: Marketing says plans can be canceled anytime, while the general terms describe a three-month subscription minimum and cancellation thirty days before the next monthly processing date after that commitment.
Sources: [7] [8]

Start with the product, not the ingredient name

Joi+Blokes advertises compounded semaglutide and compounded tirzepatide injections, describing both as administered subcutaneously. It also has a compounded liraglutide offering and a separate program for Zepbound, the branded tirzepatide injection. These are not interchangeable documentary categories. The company’s descriptions of appetite regulation, metabolic improvement and long-term weight care are promotional claims, not measurements of outcomes among patients receiving these specific programs.

The compounded semaglutide page says concentration and additional ingredients, such as B12, glycine or L-carnitine, depend on individual clinical needs. That disclosure makes the exact prescription important: a product name alone does not fully identify the preparation a patient would receive. The consulted documentation does not establish formulation-specific clinical outcomes. Our guide to approved medicines and compounded preparations explains why approval status and evidence applicability must be considered separately.

FDA states that compounded preparations do not undergo its premarket review for safety, effectiveness and quality. It recommends their use when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence or prove that a provider delivers poor care. Equally, sharing an ingredient name with an approved product does not establish equivalent evidence for every compounded formulation.

Documented treatment options and their different billing structures
Offering	Advertised charge	Important boundary
Compounded subcutaneous semaglutide	$179/month; first month $99; billed quarterly	Medication, dosing support, clinician consultations and coaching included; initial quarterly charge not specified
Compounded subcutaneous tirzepatide	$249/month; first month $149; billed quarterly	Medication, dosing support, clinician consultations and coaching included; initial quarterly charge not specified
Compounded subcutaneous liraglutide	$299/month	Virtual visits, coaching, lab access and continuous support advertised; lab access does not define included testing costs
Zepbound service	$99/month, charged as $297 for three months	Medication excluded; virtual visits, coaching, lab access and continuous support included
Zepbound vials through Lilly Direct	$349/month for 2.5 mg; $499 for 5 mg; $599 for 7.5 mg; $699 for 10 mg	Separate cash-only medication purchase; these vials are not eligible for insurance coverage; prices subject to change

Sources: [7] [9] [5] [1]

What clinical trials cannot establish about Joi+Blokes

The consulted documentation does not provide a provider-specific clinical study establishing weight outcomes, treatment persistence or adverse-event rates for Joi+Blokes patients. That is a limitation on what this review can conclude, not proof that patients do or do not benefit. The useful question is whether a claim concerns a studied medicine, a particular compounded prescription, or the platform’s delivery of care. Each requires different supporting evidence.

STEP 1 studied subcutaneous semaglutide in adults without diabetes, while SURMOUNT-1 studied subcutaneous tirzepatide in adults without diabetes. Neither was a trial of Joi+Blokes or its compounded products. Results from those trials cannot validate the platform’s formulations, vitamin blends, coaching package or an individual’s expected response. Our explanation of why a clinical trial is not a company performance report provides a framework for reading such marketing without dismissing the underlying drug research.

The same distinction applies to safety evidence. FDA has received reports of errors measuring or administering compounded GLP-1 medication, including some associated with hospitalization. Those reports are not a Joi+Blokes event rate and lack a denominator for calculating one. They do, however, reinforce a practical question for this offering: who explains the dispensed concentration, resolves instruction discrepancies and responds when a patient is uncertain? This review provides no dosing or conversion instructions.

Sources: [3] [4] [1]

Who evaluates the patient and takes responsibility?

The advertised intake begins with a health-history form and discussion with a licensed clinician. Partner providers review the history and decide whether a prescription is appropriate. Prescription products require a synchronous or asynchronous consultation, so enrollment does not guarantee a live appointment or a prescription. The terms also require informed consent before telemedicine services. These disclosures describe an evaluation pathway, but do not identify the independent clinical group that would treat each patient.

The website lists Melissa Loseke, DO, as medical director and Lauren Dulay, NP, as director of clinical operations and lead clinician. These are company-reported roles, not independently verified credentials in this review. A clinician is not necessarily a physician, and a leadership listing does not identify the person responsible for a particular prescription. Before enrollment, it would be useful to obtain the treating clinician’s name, professional designation and clinical organization.

The terms restrict services to people who have reached the age of majority where they reside. The company says it treats and ships only within the United States, but that does not confirm availability in every state; compounded semaglutide is explicitly unavailable in some states. Detailed BMI criteria and other clinical exclusions are not established here. A provider may also decide that in-person care is needed, ending platform treatment for that particular issue.

Sources: [8] [6] [7]

Read the monthly prices alongside the collection schedule

For compounded semaglutide, the advertised price is $179 per month, with the first month $99, billed quarterly. Compounded tirzepatide is $249 per month, with the first month $149, also billed quarterly. Both descriptions include medication, dosing support, clinician consultations and health coaching. The exact initial quarterly amount is not documented in the consulted passages. Prospective patients should therefore obtain the actual checkout charge rather than assume that the prominent first-month figure is the amount collected.

The liraglutide program is advertised at $299 per month with virtual provider visits, personalized coaching, lab access and continuous support. Zepbound follows a different structure: $99 per month, collected as $297 for a three-month service, with medication excluded. Its listed monthly vial costs are $349 for 2.5 mg, $499 for 5 mg, $599 for 7.5 mg and $699 for 10 mg. These are advertised presentations and prices, not dosing recommendations.

For those Zepbound vials, the medication purchase is completed through Lilly Direct after approval, is cash-only and is not eligible for insurance coverage; prices may change. Joi+Blokes separately says it assists with prior authorizations and prescription submissions but does not bill insurers directly. General statements that branded medicines may qualify for coverage do not override that vial-channel restriction. Flex HSA/FSA payment is conditional on verification, eligibility and any required letter approval, with remaining balances payable another way.

Sources: [7] [9] [5] [6]

Pharmacy and delivery claims leave practical questions open

The terms name Strive Pharmacy, Pharmacy Hub, Tailor Made Compounding Pharmacy, Cadre Labs, Empower Pharmacy, LillyDirect Self Pay Pharmacy Solutions doing business as GiftHealth, and Partell Pharmacy as partners dispensing prescriptions. That list does not establish which pharmacy fills a particular prescription or which entity compounds a given preparation. If a patient selects another pharmacy, the terms say the prescription can be sent there, but obtaining the medicine and paying that pharmacy become the patient’s responsibility.

The Zepbound page says that, after approval, patients are connected by text to Lilly Direct to pay and receive medication within 72 hours. This is a provider-advertised post-approval pathway, not a stated clinical-review deadline or independently verified delivery result. General preparation and shipping timelines for compounded products and liraglutide are not established. The consulted documentation also leaves cold-chain specifications and replacement procedures for lost, damaged or inadequately refrigerated shipments unclear.

These gaps matter because delivery is part of treatment execution, not simply convenience. FDA explicitly recommends not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. The terms also warn that prescriptions may not arrive in child-resistant containers. Before paying, ask who handles shipping problems and what packaging to expect. Our guide to reading cold-chain and delivery claims distinguishes a promise from documented handling procedures.

Sources: [8] [5] [1]

Coaching is documented; the clinical follow-up schedule is not

The compounded programs advertise unlimited health-coach visits, clinician access and support, unlimited messaging, nutrition and lifestyle support, home delivery and community access. Those features describe available channels, but do not establish the frequency of prescribing appointments, laboratory review or prescription renewal. The terms specifically warn that communication with providers may not occur in real time. Unlimited messaging should therefore not be interpreted as immediate access or a guaranteed clinical response time.

Joi+Blokes clearly states that health coaches are not doctors and cannot prescribe, diagnose medical conditions or provide specific medical advice. That boundary is useful, particularly when evaluating what the bundled support actually supplies. A patient should know how to move from a coaching conversation to the prescribing clinician when the issue is medical. NIDDK describes follow-up as an assessment of response and tolerability, not merely continued payment or access to encouragement.

A stronger public description would specify routine clinical review intervals, who reviews concerns between visits and how patients obtain help when platform care is insufficient. Those details are not established in the consulted documentation, and Spanish-language care or interpreter availability is also unconfirmed. The guide to clinical follow-up beyond renewal notices offers questions for separating a communications benefit from a defined medical monitoring process.

Sources: [7] [8] [2]

Laboratory access is not the same as included testing

The compounded-product page says labs are not required, and the Zepbound page likewise describes them as optional. Zepbound’s page offers Complete Hormone, Advanced and Comprehensive panels for people seeking additional information. A shared website module asks how testing should be arranged, but that question alone does not establish a mandatory blood draw for a particular medicine. The explicit product-page language is more informative than an inference drawn from a general testing interface.

The phrase “lab access,” included in the liraglutide and Zepbound program descriptions, does not identify which tests, specimen collections or fees are covered. The website also advertises a 65% diagnostic-lab discount for new customers using LABS65, without an expiration date in that passage, and different diagnostic pricing in New York and New Jersey. These separate offers reinforce the need for an itemized quote rather than an assumption that the treatment subscription pays every laboratory expense.

The refund policy makes diagnostic-lab purchases and lab subscriptions final and nonrefundable. That financial boundary should be clarified before ordering optional tests. The evidence question is not simply whether a large panel is available, but what the treating clinician needs to answer a specific clinical question and who reviews the results. The public pages do not establish a uniform testing protocol or make broad laboratory access proof of better clinical outcomes.

Sources: [9] [5] [7] [6] [10]

Conflicting exit terms limit confidence before enrollment

The compounded-program page advertises no membership fees and says patients can adjust or cancel anytime. The general terms, however, require a minimum of three consecutive months for subscriptions and describe automatic charges according to the product or service. They allow cancellation thirty days before the next monthly processing date after the initial commitment. The consulted documentation does not resolve how that monthly-processing language applies to quarterly billing or which rule controls each specific plan.

Refund language also differs. A product page promises an immediate refund if a prescription is deemed inappropriate. The insurance-supported GLP-1 policy says subscriptions can be canceled anytime, but paid subscription fees are nonrefundable even when the patient is not a candidate or is not approved. These statements should not be merged into a universal refund promise. Nor does an immediate-refund statement establish when money will appear in a patient’s bank account.

Prescription-product returns are not accepted, and the policy calls those sales final. Cancellation therefore should not be treated as a right to recover payment for dispensed medication, unused service time or diagnostic purchases. Before enrollment, request written confirmation of the applicable plan, initial charge, renewal date, notice deadline and outcome if no prescription is issued. Clear answers would materially improve the usefulness of the otherwise detailed program descriptions.

Sources: [7] [8] [10]

Questions & answers

Does Joi+Blokes directly provide the medical care?

Its terms say it does not practice medicine or directly provide healthcare. Instead, it connects patients with third-party medical providers. The website names clinical leaders, but the consulted documentation does not identify the independent clinical group assigned to every patient. Ask which organization and clinician will be responsible for your evaluation, prescription and medical follow-up.

Sources: [8] [6]

Is the advertised Zepbound price the full treatment cost?

No. The service costs $99 per month, collected as $297 for three months, and excludes medication. The page lists separate Lilly Direct vial prices ranging from $349 to $699 per month by presentation. Those particular vials are cash-only, are not eligible for insurance coverage and have prices subject to change. General insurance-assistance statements do not change that restriction.

Sources: [5]

Are blood tests required before joining a GLP-1 program?

The compounded-product and Zepbound pages say labs are not required. Optional testing is available, but “lab access” does not establish that testing and collection costs are included. A general testing-arrangement module does not prove a medicine-specific blood-draw requirement. Confirm the clinician’s actual requirements and any separate charges for your chosen program before purchasing a panel.

Sources: [7] [5]

Does unlimited messaging mean an immediate medical response?

No response-time guarantee is established. Joi+Blokes advertises unlimited messaging and clinician support, but its terms say provider communications may not be real-time. Health coaches cannot prescribe, diagnose or give specific medical advice. Ask how medical messages are routed, when the prescribing clinician normally responds and what happens when the concern cannot be managed through the platform.

Sources: [7] [8]

Will I receive a refund if no prescription is approved?

The public language does not support one answer for every plan. A product page promises an immediate refund when a prescription is inappropriate. The insurance-supported GLP-1 policy instead says paid subscription fees are nonrefundable even without candidacy or approval. Obtain written confirmation of which policy applies, what payment it covers and how a refund would be processed.

Sources: [7] [10]

Are Joi+Blokes compounded medications proven to match major trial results?

The consulted documentation does not establish that. STEP 1 and SURMOUNT-1 were not studies of Joi+Blokes or its compounded preparations. FDA nonapproval alone does not prove clinical inequivalence, but trial findings cannot simply be transferred to a particular compounded formulation or care program. Individual results also cannot be predicted from a trial average.

Sources: [7] [1] [3] [4]

Our assessment

Joi+Blokes provides useful public detail about its treatment options, bundled support, partner-pharmacy model and separate Zepbound costs. It also acknowledges the nonapproved status of compounded preparations and the limits of coaching. Those disclosures support a meaningful comparison of services, not a conclusion about provider-specific effectiveness. The principal unresolved issues are exact initial quarterly charges, plan-specific cancellation and refund rules, assigned clinical and pharmacy responsibilities, and defined follow-up and shipping procedures. A prospective patient’s most useful next step is to obtain those details in writing before payment, while discussing medication selection and evidence applicability with the treating clinician.

Visit Joi+Blokes’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Joi+Blokes Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product, not the ingredient name

02What clinical trials cannot establish about Joi+Blokes

03Who evaluates the patient and takes responsibility?

04Read the monthly prices alongside the collection schedule

05Pharmacy and delivery claims leave practical questions open

06Coaching is documented; the clinical follow-up schedule is not

07Laboratory access is not the same as included testing

08Conflicting exit terms limit confidence before enrollment